吸烟对经口机器人手术治疗HPV相关口咽癌结局的影响
本研究回顾性分析了2016年至2023年间接受经口机器人手术(TORS)治疗的156例HPV相关口咽鳞状细胞癌(OPSCC)患者,比较从未吸烟、既往吸烟和当前吸烟者的肿瘤学结局。结果显示,吸烟史与更晚期的病理淋巴结分期和淋巴结外侵犯相关,但吸烟并未显著影响疾病复发或死亡。
要点
- 吸烟史与更晚期的病理淋巴结分期和淋巴结外侵犯相关。
- 吸烟史未显著影响接受TORS治疗的HPV相关OPSCC患者的复发或死亡。
- 不同吸烟状态(从未、既往、当前)在辅助治疗、复发或死亡上无显著差异。
核心结论
- 吸烟史与更晚期的病理淋巴结分期和淋巴结外侵犯相关,但似乎不影响经TORS根治性治疗的HPV相关OPSCC患者的复发或死亡。
主要发现
- 中位随访2.2年期间,发现3例局部复发、6例区域复发、10例远处转移和6例死亡。
- 比较从未、既往和当前吸烟者时,吸烟者(ever smokers)表现出更晚期的病理淋巴结分期(P = .03)和淋巴结外侵犯(P = .05)。
- 比较从未和吸烟者时,从未吸烟者更年轻(P = .04),原发部位差异有边缘显著性(P = .05),吸烟者再次显示更晚期的淋巴结分期(P = .01)和淋巴结外侵犯(P = .02)。
- 按吸烟史(从未 vs 吸烟者)分析,辅助治疗、疾病复发或死亡均无显著差异;以10或20包年吸烟史截断值分析时,除年龄外(P = .01, P = .02)无其他显著差异。
临床怎么用
- 对于接受TORS治疗的HPV相关OPSCC患者,吸烟史可提示更高的淋巴结分期和淋巴结外侵犯风险,但不应据此预测复发或死亡风险增加。
局限性
- 本研究为回顾性综述,样本量有限,随访时间中位仅2.2年,可能影响长期结局的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Smoking has been identified as a risk factor for recurrence in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive chemoradiation. Whether the same prognostic significance holds with surgical treatment such as transoral robotic surgery (TORS) is less well studied. STUDY DESIGN: Retrospective review. SETTING: Tertiary care academic center. METHODS: Patients with HPV-associated OPSCC treated with TORS from January 2016 to December 2023 were included. Demographics, smoking history, disease characteristics, treatment, and oncologic outcomes were collected. RESULTS: 156 patients were included. 87.2% were male with median age 60.0 years. Seventy-seven were never smokers, 63 former smokers, and 16 current smokers, with a median 20 pack-years among ever smokers. Three local, 6 regional, and ten distant metastases were identified, with 6 deaths, over a median 2.2 years of follow up. When comparing never, former, and current smokers, ever smokers demonstrated more advanced pathologic nodal staging (P = .03) and extranodal extension (P = .05). When comparing never and ever smokers, never smokers were younger (P = .04), and primary site differed with borderline significance (P = .05). Ever smokers again had more advanced nodal stage (P = .01) and extranodal extension (P = .02). There were no significant differences in adjuvant treatment, disease recurrence, or death by smoking history. There were no significant differences apart from age when analyzed using a 10 or 20-pack-year smoking history cutoff (P = .01, P = .02). CONCLUSION: Smoking history is associated with more advanced nodal stage and extranodal extension. However, smoking does not appear to influence recurrence or death in the setting of HPV-associated OPSCC definitively treated with TORS.
引用
- Tong JY, Bzhilyanskaya V, Molitoris JK, et al. Does Smoking Influence Outcomes in Human Papillomavirus-Associated Oropharyngeal Cancer Treated with Transoral Robotic Surgery? Otolaryngol Head Neck Surg. 2026. PMID: 41603566. doi:10.1002/ohn.70138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。